Industry discussions reveal that AI in drug discovery is currently hindered by a reliance on limited existing data, meaning the technology accelerates routine tasks but has yet to yield genuinely novel scientific breakthroughs. Consequently, experts suggest the field's most immediate, tangible impact may actually be found in bottom-up, patient-centric care management rather than top-down drug development.